Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma
ConclusionsOur study suggests that the ZA use was associated with a decreased risk of SRE for patients with SRE history. However, no preventive effects of ZA were observed for patients without history.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Health Insurance | Insurance | Myeloma | Orthopaedics | Prostate Cancer | Reclast | Study | Zometa